Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series
Introduction: Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial lung disease. Methods: Patients registered within the Dutch GIST Registry (DGR) were reviewed. For the patients ident...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621924000036 |
| _version_ | 1827313647498559488 |
|---|---|
| author | Deborah van de Wal Evelyne Roets Roos F. Bleckman Jorn Nützinger Birthe C. Heeres J. Martijn Kerst Mahmoud Mohammadi Anna K.L. Reyners Ingrid M.E. Desar Astrid W. Oosten Neeltje Steeghs Winette T.A. van der Graaf |
| author_facet | Deborah van de Wal Evelyne Roets Roos F. Bleckman Jorn Nützinger Birthe C. Heeres J. Martijn Kerst Mahmoud Mohammadi Anna K.L. Reyners Ingrid M.E. Desar Astrid W. Oosten Neeltje Steeghs Winette T.A. van der Graaf |
| author_sort | Deborah van de Wal |
| collection | DOAJ |
| description | Introduction: Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial lung disease. Methods: Patients registered within the Dutch GIST Registry (DGR) were reviewed. For the patients identified with an imatinib-induced pneumonitis we reported the time on imatinib to develop pneumonitis, how the pneumonitis was diagnosed, graded and managed, and how the GIST treatment was managed. Cases: Of the 1934 patients registered in the DGR, 1161 patients received imatinib at some point, of which nine patients (0.8 %) were identified with an imatinib-induced pneumonitis. At time of the pneumonitis, patients received a daily imatinib dose of 200–400 mg for a mean duration of 486 days. One patient was able to continue imatinib in a lower dose, in the other eight patients imatinib was interrupted, and six of these patients started prednisolone treatment. After management of the imatinib-induced pneumonitis, four patients stopped imatinib permanently, two patients were rechallenged with imatinib, and two patients started treatment with second-line sunitinib. Conclusion: Imatinib-induced pneumonitis is a rare side effect, which may affect GIST management considerably. After the management of imatinib-induced pneumonitis, clinicians are left with difficult treatment dilemmas. |
| first_indexed | 2024-03-08T04:06:18Z |
| format | Article |
| id | doaj.art-17c1d620b6f541a1887eb4d8df70b1e7 |
| institution | Directory Open Access Journal |
| issn | 2666-6219 |
| language | English |
| last_indexed | 2024-04-24T22:18:49Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Problems in Cancer: Case Reports |
| spelling | doaj.art-17c1d620b6f541a1887eb4d8df70b1e72024-03-20T06:11:28ZengElsevierCurrent Problems in Cancer: Case Reports2666-62192024-03-0113100280Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case seriesDeborah van de Wal0Evelyne Roets1Roos F. Bleckman2Jorn Nützinger3Birthe C. Heeres4J. Martijn Kerst5Mahmoud Mohammadi6Anna K.L. Reyners7Ingrid M.E. Desar8Astrid W. Oosten9Neeltje Steeghs10Winette T.A. van der Graaf11Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the NetherlandsDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the NetherlandsDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsDepartment of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, the NetherlandsDepartment of Radiology, The Netherlands Cancer Institute, Amsterdam, the NetherlandsDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the NetherlandsDepartment of Medical Oncology, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsDepartment of Medical Oncology, Radboud University Medical Center, Nijmegen, the NetherlandsDepartment of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the NetherlandsDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Clinical Pharmacology, The Netherlands Cancer Institute, the NetherlandsDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands; Corresponding author at: Department of Medical Oncology, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.Introduction: Imatinib has led to a phenomenal progress in the treatment of GIST. A rare and lesser-known side effect of imatinib is pneumonitis, an uncommon multicausal interstitial lung disease. Methods: Patients registered within the Dutch GIST Registry (DGR) were reviewed. For the patients identified with an imatinib-induced pneumonitis we reported the time on imatinib to develop pneumonitis, how the pneumonitis was diagnosed, graded and managed, and how the GIST treatment was managed. Cases: Of the 1934 patients registered in the DGR, 1161 patients received imatinib at some point, of which nine patients (0.8 %) were identified with an imatinib-induced pneumonitis. At time of the pneumonitis, patients received a daily imatinib dose of 200–400 mg for a mean duration of 486 days. One patient was able to continue imatinib in a lower dose, in the other eight patients imatinib was interrupted, and six of these patients started prednisolone treatment. After management of the imatinib-induced pneumonitis, four patients stopped imatinib permanently, two patients were rechallenged with imatinib, and two patients started treatment with second-line sunitinib. Conclusion: Imatinib-induced pneumonitis is a rare side effect, which may affect GIST management considerably. After the management of imatinib-induced pneumonitis, clinicians are left with difficult treatment dilemmas.http://www.sciencedirect.com/science/article/pii/S2666621924000036ImatinibAdverse eventGISTPneumonitisInterstitial lung diseaseCase series |
| spellingShingle | Deborah van de Wal Evelyne Roets Roos F. Bleckman Jorn Nützinger Birthe C. Heeres J. Martijn Kerst Mahmoud Mohammadi Anna K.L. Reyners Ingrid M.E. Desar Astrid W. Oosten Neeltje Steeghs Winette T.A. van der Graaf Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series Current Problems in Cancer: Case Reports Imatinib Adverse event GIST Pneumonitis Interstitial lung disease Case series |
| title | Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series |
| title_full | Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series |
| title_fullStr | Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series |
| title_full_unstemmed | Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series |
| title_short | Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series |
| title_sort | treatment dilemmas in patients with gastrointestinal stromal tumors gist who experienced imatinib induced pneumonitis a case series |
| topic | Imatinib Adverse event GIST Pneumonitis Interstitial lung disease Case series |
| url | http://www.sciencedirect.com/science/article/pii/S2666621924000036 |
| work_keys_str_mv | AT deborahvandewal treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT evelyneroets treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT roosfbleckman treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT jornnutzinger treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT birthecheeres treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT jmartijnkerst treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT mahmoudmohammadi treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT annaklreyners treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT ingridmedesar treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT astridwoosten treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT neeltjesteeghs treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries AT winettetavandergraaf treatmentdilemmasinpatientswithgastrointestinalstromaltumorsgistwhoexperiencedimatinibinducedpneumonitisacaseseries |